Sarah Yuan
Chief Technology Officer Cabaletta Bio
Dr. Yuan joined Cabaletta in June 2024 as Chief Technology Officer to oversee Technical Development, Manufacturing, Supply Chain and CMC Strategy organizations. Dr. Yuan brings more than 20 years of CMC experience from a broad range of leading biopharmaceutical companies. Prior to joining Cabaletta, Dr. Yuan was Chief Technical Operations Officer at Sigilion Therapeutics, a wholly owned subsidiary of Eli Lilly & Co, where she led the CMC efforts to develop a novel cell therapy based on Sigilion’s Shielded Living Therapeutics platform. Before that, Dr. Yuan served as the Vice President of Process and Analytical Development at 2seventy bio, the oncology spinoff of bluebird bio, where she was instrumental in getting three cell therapy products approved, in addition to advancing a preclinical product through IND clearance. Earlier in her career, Dr. Yuan held various leadership roles in External Manufacturing, Technical Development, Manufacturing Sciences, and CMC Strategies at Sanofi, Bioverativ, Biogen, Agenus (formerly known as Antigenics) and Millipore. Dr. Yuan received her Ph.D. in Chemical Engineering from the University of Wisconsin-Madison, and B.S. from University of California, Berkeley.
Seminars
- Identify key cost drivers in cell therapy manufacturing and discuss practical strategies to reduce them without compromising quality
- Debate approaches to efficient scale-out and scale-up that enable broader patient access while meeting regulatory and quality standards
- Examine how automation enables scalable, parallelised production of autologous CAR-T therapies without compromising quality
- Discuss how streamlined, modular manufacturing platforms can lower costs and accelerate patient access
